The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
Modern Pathology2012Vol. 25(9), pp. 1193–1202
Citations Over TimeTop 10% of 2012 papers
Umberto Gianelli, Claudia Vener, Anna Bossi, Ivan Cortinovis, Alessandra Iurlo, Nicola Stefano Fracchiolla, Federica Savi, Alessia Moro, Federica Irene Grifoni, Chiara De Philippis, Tommaso Radice, Silvano Bòsari, Giorgio La Nasa, Agostino Cortelezzi
Related Papers
- → Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts(2014)96 cited
- → Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation(2019)26 cited
- → The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib(2018)30 cited
- → A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic(2020)12 cited
- → PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION(2022)